UK markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.04+0.25 (+0.38%)
As of 03:54PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close64.79
Open64.87
Bid65.01 x 1100
Ask65.02 x 1300
Day's range64.61 - 65.11
52-week range61.73 - 76.56
Volume2,891,186
Avg. volume5,492,947
Market cap201.599B
Beta (5Y monthly)0.17
PE ratio (TTM)34.41
EPS (TTM)1.89
Earnings dateN/A
Forward dividend & yield1.45 (2.24%)
Ex-dividend date10 Aug 2023
1y target est82.69
  • Zacks

    Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca

    Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.

  • Reuters

    AstraZeneca, AI biologics firm Absci tie up on cancer drug

    Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.

  • Reuters

    UPDATE 2-AstraZeneca, AI biologics firm Absci tie up on cancer drug

    Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday. Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.